國家衛生研究院 NHRI:Item 3990099045/13109

NHRI > Institute of Biotechnology and Pharmaceutical Research > Hsing-Pang Hsieh > Periodical Articles > Item 3990099045/13109

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13109

Title:	Tumor-agnostic inhibitors in oncology: A new phase for precision medicine
Authors:	Li, MC;Hsieh, HP
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	The study of precision medicine is flourishing in recent decades. Tumor-agnostic therapy is one of the targeted therapies, which can treat the malignant cells regardless of where they grow. Herein we reviewed currently the U.S. FDA-approved tumor-agnostic therapies: one monoclonal antibody as a PD-1 inhibitor called pembrolizumab and four small-molecule kinase inhibitors, larotrectinib, entrectinib, selpercatinib, and pralsetinib. We also summarized the reported synthetic routes toward three drugs and some developing candidates under clinical trials as tumor-agnostic therapy.
Date:	2020-12-10
Relation:	Journal of the Chinese Chemical Society. 2020 Dec 10;67(12):2216-2224.
Link to:	http://dx.doi.org/10.1002/jccs.202000377
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0009-4536&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000597230800001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85097413956
Appears in Collections:	[Hsing-Pang Hsieh] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI000597230800001.pdf		1559Kb	Adobe PDF	442	View/Open